Skip to main content
Erschienen in: Journal of Neurology 2/2011

01.02.2011 | Letter to the Editors

Recurrent tumefactive demyelination without evidence of multiple sclerosis or brain tumour

verfasst von: A. Häne, M. Bargetzi, E. Hewer, M. Bruehlmeier, A. Khamis, U. Roelcke

Erschienen in: Journal of Neurology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sirs, …
Literatur
1.
Zurück zum Zitat Lucchinetti CF, Gavrilova RH, Metz I et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775CrossRefPubMed Lucchinetti CF, Gavrilova RH, Metz I et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775CrossRefPubMed
2.
Zurück zum Zitat Ng S, Butzkueven H, Kalnins R et al (2007) Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. J Clin Neurosci 14:1126–1129CrossRefPubMed Ng S, Butzkueven H, Kalnins R et al (2007) Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. J Clin Neurosci 14:1126–1129CrossRefPubMed
3.
Zurück zum Zitat Kim DS, Na DG, Kim KH et al (2009) Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 251:467–475CrossRefPubMed Kim DS, Na DG, Kim KH et al (2009) Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 251:467–475CrossRefPubMed
4.
Zurück zum Zitat Jain R, Ellika S, Lehmann NL et al (2010) Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT? J Neurooncol 97:383–388CrossRefPubMed Jain R, Ellika S, Lehmann NL et al (2010) Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT? J Neurooncol 97:383–388CrossRefPubMed
5.
Zurück zum Zitat Kepes JJ (1993) Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 33:18–27CrossRefPubMed Kepes JJ (1993) Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 33:18–27CrossRefPubMed
6.
Zurück zum Zitat Sloand EM, Rezvani K (2008) The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 45:39–48CrossRefPubMed Sloand EM, Rezvani K (2008) The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 45:39–48CrossRefPubMed
7.
Zurück zum Zitat Derweesh IH, Tannenbaum CS, Rayman PA et al (2003) Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat Res 116:29–51PubMed Derweesh IH, Tannenbaum CS, Rayman PA et al (2003) Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat Res 116:29–51PubMed
8.
Zurück zum Zitat Xia L, Lin S, Wang ZC et al (2009) Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev 32:171–179CrossRefPubMed Xia L, Lin S, Wang ZC et al (2009) Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev 32:171–179CrossRefPubMed
9.
Zurück zum Zitat Nadkar MY, Deore RA, Singh R (2008) Tumefactive demyelination. J Assoc Physicians India 56:901–903PubMed Nadkar MY, Deore RA, Singh R (2008) Tumefactive demyelination. J Assoc Physicians India 56:901–903PubMed
10.
Zurück zum Zitat Mao-Draayer Y, Braff S, Pendlebury W et al (2002) Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology 59:1074–1077CrossRefPubMed Mao-Draayer Y, Braff S, Pendlebury W et al (2002) Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology 59:1074–1077CrossRefPubMed
Metadaten
Titel
Recurrent tumefactive demyelination without evidence of multiple sclerosis or brain tumour
verfasst von
A. Häne
M. Bargetzi
E. Hewer
M. Bruehlmeier
A. Khamis
U. Roelcke
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 2/2011
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-010-5722-1

Weitere Artikel der Ausgabe 2/2011

Journal of Neurology 2/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.